TBPH
Theravance Biopharma Inc - USData as of 2026 Q2 (06-30) · 13F snapshot
Summary
Theravance Biopharma Inc - US (TBPH) is held as common stock by 4 tracked hedge-fund managers, with a combined reported value of ~$14.23M; the largest are Ken Griffin, Renaissance Technologies, Izzy Englander. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 2 added, 1 trimmed, 1 closed. 1 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Mixed
Common-stock holders41 also report options
Congress trades1
Price$17.03vs quarter-end+0.18%
Sectors0
This quarter's moves
Top holderNew1
Added2
Trimmed / sold2
Ken GriffinCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $523.6K— of portfolio30,8002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinPUT | $523.6K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.